W. Piszczek

Efficacy of high-dose corticosteroid-based treatment for chronic lymphocytic leukemia patients with p53 abnormalities in the era of B-cell receptor inhibitors.

J. Zaucha, A. Waszczuk-Gajda, B. Puła, 2020, Advances in medical sciences.

Long-term Efficacy of Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia: Results of the Polish Adult Leukemia Study Group Observational Study

J. Zaucha, T. Robak, K. Giannopoulos, 2020, AntiCancer Research.

Efficacy and toxicity of compassionate ibrutinib use in relapsed/refractory chronic lymphocytic leukemia in Poland: analysis of the Polish Adult Leukemia Group (PALG)

J. Zaucha, T. Robak, K. Giannopoulos, 2017, Leukemia & lymphoma.

Ibrutinib discontinuation in patients with relapsed or refractory chronic lymphocytic leukemia treated in a compassionate use program: A report from the Polish Adult Leukemia Study Group (PALG).

J. Zaucha, K. Warzocha, B. Puła, 2019, Advances in clinical and experimental medicine : official organ Wroclaw Medical University.

Outcome of SARS-CoV-2-Infected Polish Patients with Chronic Lymphocytic Leukemia

M. Gajewska, K. Giannopoulos, J. Drozd-Sokołowska, 2022, Cancers.